Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members

Amer Hadi a,*, Mikkel Werge a, Klaus Tjelle Kristiansen b, Ulf Gottstrup Pedersen b, John Gásdal Karstensen a, c, Srdan Novovic a, c, Lise Lotte Gluud a, c, **

a Pancreatitis Centre East, Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
b Intensive Care Unit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
c Department of Clinical Medicine, University of Copenhagen, Denmark

ABSTRACT

Background/Objectives: Abdominal pain is one of the known symptoms associated with coronavirus disease 2019. Little is known about the development of acute pancreatitis as a complication of severe acute respiratory syndrome coronavirus 2 infection. This case report describes the presentation of acute pancreatitis in two of three family members with severe COVID-19 infection.

Methods: Data were collected from three family members admitted with COVID-19 to the intensive care unit in March 2020. This study was reviewed and approved by the local data and ethics committee (31-1521-253).

Results: Two of the three family members were diagnosed with acute pancreatitis associated with SARS-CoV-2. Other causes of acute pancreatitis were excluded for both patients (including alcohol, biliary obstruction/gall stones, drugs, trauma, hypertriglyceridemia, hypercalcemia, and hypotension).

Conclusions: These cases highlight acute pancreatitis as a complication associated with COVID-19 and underlines the importance of measuring pancreas-specific plasma amylase in patients with COVID-19 and abdominal pain.

© 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.

1. Introduction

The ongoing pandemic with coronavirus disease-19 (COVID-19) has reached above 2.810.000 confirmed cases worldwide [1]. The severity of the disease ranges from subclinical infections to severe illness requiring hospital admission [2,3]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections primarily affect the respiratory tract [4], but gastrointestinal symptoms such as nausea, vomiting and diarrhea also occur [5,6]. Abdominal pain is most frequent in patients who are severely ill [7]. Viral RNA has been found in fecal specimens despite negative respiratory tests [8,9] and in gastrointestinal epithelium [5] suggesting a possible fecal-oral transmission route.

Acute pancreatitis is the most frequent gastrointestinal cause of hospital admission in the United States [10]. The development of acute pancreatitis is multifactorial requiring predisposition and relevant injury [11]. The most common causes are gallstones and alcohol abuse, but viral-induced acute pancreatitis has also been described [12]. This case report describes three first-degree relatives with severe COVID-19, two of which developed severe acute pancreatitis.

2. Methods

Data were collected from three family members admitted with COVID-19 to the Intensive Care Unit at Copenhagen University Hospital Hvidovre in the Capital Region of Denmark in March 2020. Acute pancreatitis was diagnosed according to the Atlanta classification. Throat swab samples and tracheal aspirates were collected from all patients and SARS-CoV-2 was detected using real time transcription—polymerase chain reaction assay. Blood samples and diagnostic imaging were performed according to the best clinical practice. This study was reviewed and approved by the local...
data and ethics committee (31-1521-253).

3. Results

Two of the three family members were diagnosed with acute pancreatitis associated with SARS-CoV-2. Other causes of acute pancreatitis were excluded for both patients (including alcohol, biliary obstruction/gallstones, drugs, trauma, hypertriglyceridemia, hypercalcemia, and hypotension).

Case 1. (daughter): A 47-year-old previously healthy woman was admitted to the emergency department at our hospital with a fever, headache and neck pain for one week and anorexia, sore throat and dyspnea for a couple of days. The patient had a minimal alcohol intake and did not smoke. At admission, the patient was awake and hemodynamically stable with a mean arterial pressure of 93 mmHg. The patient showed signs of acute respiratory distress with a respiratory rate of 40/min, an oxygen-saturation (SaO2) of 80% on 15L of oxygen/min requiring intubation and mechanical ventilation. A chest X-ray showed bilateral massive opacities with a respiratory rate of 40/min, an oxygen-saturation (SaO2) of 80% on 15L of oxygen/min requiring intubation and mechanical ventilation. A chest X-ray showed bilateral massive opacities with air bronchograms (Fig. 1). The patient tested positive for SARS-CoV-2 RNA. The patient developed acute kidney failure and continuous veno-venous hemodialysis (CVVHD) was initiated at day two. The respiratory changes worsened over the next two weeks and the chest X-ray showed increasing perihilar involvement and consolidation. Treatment included fluid resuscitation and intravenous antibiotics. At admission, the patient experienced abdominal pain and the clinical assessment showed direct epigastric and periumbilical tenderness. Slight abdominal distension was noted at day four and remitted afterwards. The amylase-level increased from 85 U/L on the day of admission to 934 U/L on day six (Fig. 2). The Modified Glasgow Acute Pancreatitis Score was 5 points indicating severe acute pancreatitis. Calcium-levels were normal and earlier measurements of triglycerides were also normal. A daily decline of amylase was measured afterwards until normal range was reached at day 22. As of last update, the patient is still in ICU.

Case 2. (mother): A 68-year-old woman who was admitted to the Gastrounit at our hospital two days after Case 1. Comorbidities included hypertension, hypothyroidism and osteoporosis treated with losartan, levothyroxine, alendronate and cyanocobalamin. The patient was admitted with epigastric pain and fever as well as vomitus, diarrhea, fatigue and polydipsia. At admission, the patient had a temperature of 39.7°C rectally, a C-reactive protein of 77 mg/L, tachypnea (30 breaths/min), hypoxia (8.5 kPa) and hypopcapnia (3.8 kPa) on 4L of oxygen/min. Initial chest radiograph showed diffuse interstitial opacities. The respiratory insufficiency progressed during the first two days and the patient was intubated and admitted to the intensive care unit for mechanical ventilation. The patient tested positive for SARS-CoV-2 RNA. On day 3, the patient developed acute kidney failure and CVVHD treatment was initiated. Renal function did not recover, and the respiratory distress continued to worsen with bilateral progression of opacities peripherally and perihilar with consolidation. Treatment included fluid resuscitation and intravenous antibiotics.

At admission, the patient experienced abdominal pain and the clinical assessment showed direct epigastric and peribulbular tenderness. Slight abdominal distension was noted at day four and remitted afterwards. The amylase-level increased from 85 U/L on the day of admission to 934 U/L on day six (Fig. 2). The Modified Glasgow Acute Pancreatitis Score was 5 points indicating severe acute pancreatitis. Calcium-levels were normal and earlier measurements of triglycerides were also normal. A daily decline of amylase was measured afterwards until normal range was reached at day 22. As of last update, the patient is still in ICU.

Case 3. (father): One week after Case 1 was admitted, a 71-year-old man was admitted to the emergency department. He was previously healthy, had a very low alcohol intake and did not smoke. Three days before admission the patient experienced gastrointestinal symptoms with anorexia and diarrhea as well as a fever (38.9°C), dry cough, general malaise and fatigue. Initially, the patient was hypoxic, but reached a normal respiratory rate of 17 breaths/min and saturation (9.7 kPa) after treatment with oxygen (8L/min). A chest X-ray showed bilateral perihilar and peripherally with consolidation. The respiratory problems worsened and on day three, the patient developed acute respiratory distress. The patient was transferred to the intensive care unit and received invasive mechanical ventilation and intravenous antibiotics. Due to bradycardia and hypotension, noradrenaline and dopamine was added. After three weeks, the patient developed increasing creatinine and oliguria. The outcome was fatal. The patient did not show evidence of acute pancreatitis (Fig. 2).

4. Discussion

Previous studies have reported acute inflammation in the pancreas due human immunodeficiency virus, mumps, Cytomegalovirus, Coxsackievirus B and Influenza A (H1N1). The incidence of viral acute pancreatitis is unknown [12].

We report two first-line relatives with acute pancreatitis associated with SARS-CoV-2 infection. According to the current guidelines [13], the diagnosis of acute pancreatitis requires at least two of the three following signs: 1) abdominal pain, 2) amylase or lipase
>3 times the upper normal limit, and 3) characteristic findings on
diagnostic imaging. The two cases described in this paper had se-
vere acute pancreatitis, which itself may lead to multiorgan failure
including adult respiratory distress and kidney failure as seen in
both patients. On the other hand, COVID-19 may also lead to same
organ failures and it is therefore not possible to evaluate if the acute
pancreatitis contributed to the severe course of the disease. The
third family member who was admitted to the intensive care unit
with COVID-19 had respiratory distress and gastrointestinal
symptoms, but not acute pancreatitis. Additionally two family
members (not described) tested positive for SARS-CoV-2, but only
had mild symptoms and did not require hospitalization. We did not
identify a likely explanation for why only two of the five cases
developed acute pancreatitis.

Previous studies have confirmed that COVID-19 may be associated
with gastrointestinal symptoms including abdominal pain [5-7]
and have identified viral RNA in the gastrointestinal tract [5,8,9].
Wang et al. reported at admission 17% of 52 patients with COVID-19
had slightly abnormal amylase or lipase [14]. Several factors may
contribute to the development of acute pancreatitis including
pancreatic autodigestion, enzyme activation, complement system
activation, microcirculation disturbance theory, leukocyte excess-
avative activation, and pancreatic acinar cell apoptosis and necrosis.
Theoretically viral pancreatitis develops due to direct destruction of
pancreatic acinar cells by inflammation and edema. Alternatively,
damage to the pancreatic acinar cells by the virus could lead to a
leaking intracellular enzyme or precipitates a process of cell death.
The entry receptor Angiotensin-converting enzyme 2 (ACE2) for
SARS-CoV-2 has been identified in the gastrointestinal epithelium
of infected cases. During the 2002-2004 outbreak, SARS-CoV used
ACE2 for entry to host cells. Increased expression in pancreatic is-
lets were observed, leading eventually to acute diabetes [15].
Genome sequences of SARS-CoV have shown that 79.6% are shared
with SARS-CoV-2 [6]. The expression of ACE2 in the pancreas
during SARS-CoV-2 infection could therefore lead to acute
inflammation.

Nevertheless, the presented cases underline the importance of
measuring lipase or amylase in patients with SARS-CoV-2 in-
fecions, especially if patients experience abdominal pain.

Author contributions

Dr Hadi, Amer had full access to all of the data in the study and
takes responsibility for the integrity of the data and the accuracy
of the data analysis. Drs Hadi, Amer, Werge, Mikkel P., Gluud, Lise L,
and Novovic, S contributed equally. Concept and design: Dr Gluud,
Lise L. Acquisition, statistical analysis, or interpretation of data: Drs
Hadi, Amer, Werge, Mikkel P., Gluud, Lise L, and Novovic S. Drafting
of the manuscript: Dr Hadi, Amer. Critical revision of the manu-
script for important intellectual content: all authors.

Funding/support

This work did not receive financial support.

Declaration of competing interest

None reported.

References

[1] Johns Hopkins CSSE. Coronavirus COVID-19 (2019-nCoV). Coronavirus COVID-
19 glob cases by Johns Hopkins CSSE 2020:1.

[2] Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3,062
COVID-19 patients: a meta-analysis. J Med Virol 2020. https://doi.org/
10.1002/jmv.25884.

[3] Nobel YR, Pihips M, Zucker J, Lebowtih W, Wang TC, Sobieszczyn ME, et al.
Gastrointestinal symptoms and COVID-19: case-control study from the United
States. Gastroenterology 2020. https://doi.org/10.1053/j.gastro.2020.04.017.

[4] Li L, Huang T, Wang Y, Wang Z, Liang Y, Huang T, et al. Novel coronavirus
patients’ clinical characteristics, discharge rate and fatality rate of meta-
analysis. J Med Virol 2019. https://doi.org/10.1002/jmv.25757. 2020:
jmv.25757.

[5] Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal
infection of SARS-CoV-2. Gastroenterology 2020. https://doi.org/10.1053/
j.gastro.2020.02.055.

[6] Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol
Hepatol 2020. https://doi.org/10.1111/jgh.15047. 2020:
jmv.25884.

[7] Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in
COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther
2020:1-9. https://doi.org/10.1111/apt.15731.

[8] Cheung KS, Hung IF, Chan PP, Lung KC, Tso E, Liu R, et al. Gastrointestinal
manifestations of SARS-CoV-2 infection and virus load in fecal samples from
the Hong Kong cohort and systematic review and meta-analysis. Gastroen-
terology 2020. https://doi.org/10.1053/j.gastro.2020.03.065.

[9] Amico FD, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-
19 infection: pathogenesis, epidemiology, prevention and management. Clin
Gastroenterol Hepatol 2020. https://doi.org/10.1016/j.cgh.2020.04.001.

[10] Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, et al.
Burden of gastrointestinal disease in the United States: 2012 update.
Gastroenterology 2012;143:313. https://doi.org/10.1053/j.gastro.2012.08.002.

[11] Testoni PA. Acute recurrent pancreatitis: etiopathogenesis, diagnosis and
treatment. World J Gastroenterol 2014;20:16891–901. https://doi.org/
10.3748/wjg.v20.i45.16891.

[12] Lankisch PG, Apte M, Banks PA. Supplementary appendix: acute pancreatitis.
Lancet 2015;6736:1–32.

[13] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MC, et al.
Classification of acute pancreatitis - 2012: revision of the Atlanta classification
and definitions by international consensus. Gut 2013;62:102–11. https://
doi.org/10.1136/gutjnl-2012-302779.

[14] Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in
patients with COVID-19 pneumonia. Gastroenterology 2020. https://doi.org/
10.1053/j.gastro.2020.03.055.

[15] Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor
damages islets and causes acute diabetes. Acta Diabetol 2010;47:193–9.
https://doi.org/10.1007/s00592-009-0105-4.